Ampreloxetine (TFA)

• Product Name Alternative:

  AG-013736-d3, AG-013736 13CD3

• UNSPSC Description:

  Ampreloxetine (TD-9855) TFA is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine TFA has the potential for the research of neurogenic orthostatic hypotension[1][2].

• Target Antigen:

  5-HT Receptor; Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/ampreloxetine-tfa.html

• Purity:

  98.30

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC1=C(OCC2=CC=CC=C2C3CCNCC3)C(F)=CC(F)=C1.O=C(O)C(F)(F)F

• Molecular Weight:

  435.36

• References & Citations:

  [1]Smith JA, et al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2):pyu027. |[2]Kaufmann H, et al. Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin Auton Res. 2021 Dec;31(6):699-711.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Phase 3

• CAS Number:

  1227056-85-0